SHELTON, Conn., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the unexpected death of Dr. Robert Medve, the company's Chief Medical Officer. Dr. Medve had served as Chief Medical Officer since June 2014.
Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics, commented, "It is with great sadness that we announce the unexpected passing of Dr. Robert Medve. During his brief tenure at Cara, we benefited greatly from Rob's expertise in drug development and pain management, as well as his dedication and commitment. On behalf of the entire Cara team, I would like to offer our deepest sympathies to the Medve family during this difficult time."
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.